The Biological Answer Is Not in Another Million Years Since Evolution
Here is the Tale of $500 Million Illusion: How Big Tech Is Selling Hope Through AI Biology
Curator’s Note: The article critiques the optimistic claims surrounding a $500 million investment by Mark Zuckerberg to use AI in combating human diseases. The author emphasizes that while AI offers promising tools for understanding complex biological systems, it cannot single-handedly eradicate diseases, as these conditions are multifaceted and deeply rooted in biological, environmental, and behavioral factors. The narrative’s escalation from “advancing biological modeling” to “ending diseases” is seen as a misunderstanding of science’s incremental progress. The investment is essential for future discovery, but the implied timeline for drastic changes is misleading. Ultimately, genuine advancements will emerge gradually rather than as swift cures. This compelling essay was written by Dr Michael Broadly, a retired health scientist and public health officer who also lead the Health and Science publication on Medium.com.
Dear subscribers,
First I’d like to give you the context of my story so my points make sense to you. I decided to write this thought-provoking and educational story after reading several news articles and social media posts that said, “Mark Zuckerberg bets $500M on using AI to end human disease.” It is not criticism but an offer of perspectives from my half-century of experience in the health sciences.
There’s something undeniably seductive about a bold scientific promise. It doesn’t just capture attention but imagination, too. Over the decades, I’ve seen how a well-crafted promise can travel faster than the science itself, especially when it taps into something deeply human: our desire to overcome suffering on Earth.
Rhetorical remarks such as ‘end disease,’ ‘cure everything,’ or ‘rewrite the biological destiny of humankind’ aren’t just statements. I see them as aspirations that resonate across cultures and generations. And when they’re presented with confidence, they can feel almost within reach, even when the underlying science is still finding its footing. However, they could also be misleading and give the public false hope.
This time, the promise arrives wrapped in the language of artificial intelligence, backed by a half-billion-dollar investment, and amplified through headlines engineered for maximum emotional impact. It’s polished, persuasive, and perfectly timed for an era that already sees AI as a kind of modern oracle.
But if we slow down for a moment (as scientists, as thinkers, and as everyday observers), we begin to notice something more layered beneath the surface. The story isn’t false, but it isn’t quite what it appears to be either.
I see this not as a deception, in the strict sense. But certainly, an inflation of expectations, so I want to add some clarity into this rhetoric.
The Anatomy of a Modern Scientific Narrative
At its core, the recent announcement is quite straightforward when stripped of its promotional sheen.
A significant investment is being directed into AI-driven biological research, with the goal of improving our understanding of how human cells function and, by extension, how diseases emerge and progress.
That, in itself, is both admirable and necessary. In fact, it reflects a long-standing challenge in biomedical science that many outside the field don’t fully appreciate.
For decades, researchers have been working with an inherent limitation: we tend to observe fragments rather than whole systems.
We isolate variables, simplify conditions, and focus on manageable pieces of a much larger puzzle. It’s effective but incomplete.
Cells, however, don’t behave in isolation. They are dynamic, responsive, and deeply interconnected with their environment.
Studying them in fragments is a bit like trying to understand Melbourne’s traffic patterns by observing a single intersection during off-peak hours; you’ll learn something, but you’ll miss the bigger picture entirely.
Artificial intelligence offers a genuinely promising shift here. It allows researchers to integrate vast and complex datasets, identify patterns that would otherwise remain hidden, and simulate biological processes at a scale previously unimaginable. In principle, this could move us closer to a systems-level understanding of life itself.
In theory, that’s transformative. In practice, it remains an unfolding experiment.
From Scientific Ambition to Public Imagination
This is where the narrative begins to drift slightly off course. Somewhere between the technical proposal and the public headline, the language starts to stretch.
“Advancing biological modeling” evolves into “ending human disease.”
Now, that leap doesn’t come from the science itself. It emerges from how the science is communicated, packaged, simplified, and broadcast for broader appeal.
I’ve seen this pattern many times over the years, and it’s almost formulaic in its progression.
First, a complex and important problem is identified. Then, a powerful new tool enters the scene, often with genuine potential.
A bold vision is attached to that tool, which is then simplified for public consumption. And before long, hope begins to expand much faster than the underlying evidence can support.
What we end up with is a narrative that feels compelling and even inspiring but sits in a slightly uncomfortable space between aspiration and reality.
The Illusion Is Not the Investment But the Timeline
Now, let me be clear, because this point often gets lost in the noise.
The investment itself is not an illusion. Funding science, especially foundational, infrastructure-level science, is absolutely essential. Without it, progress stalls, collaborations weaken, and innovation slows to a crawl.
Large-scale funding enables researchers to build tools, share data, and explore ideas that would otherwise remain out of reach. In that sense, this initiative is both valuable and necessary.
The illusion lies in something more subtle: the implied timeline.
There’s an unspoken suggestion that such a significant investment brings us meaningfully closer to “ending disease” within a timeframe that feels tangible, perhaps even within our lifetime.
From a scientific perspective, I know that the implication doesn’t hold up. For instance:
Disease is not a single entity that can be solved with a fragmented or even unified approach. It is a vast and complex ecosystem of conditions, each with its own mechanisms, risk factors, and trajectories.
We’re talking about genetic disorders, infectious diseases, cancers, autoimmune conditions, neurodegenerative illnesses, and a growing recognition of psychosomatic and stress-related disorders.
Each of these operates across different biological scales and is influenced by a mix of genetics, environment, behavior, and sheer randomness.
To suggest that one technological pathway, even one as powerful as AI, could “end” all of them is not just optimistic. It borders on being conceptually naïve.
AI as a Tool, Not a Miracle
Artificial intelligence is an extraordinary tool, but it’s still just a tool. It cannot just eradicate diseases that evolved over millions of years.
These artificial intelligence tools, no matter how sophisticated, do not understand biology in a human sense. They don’t form insights through lived experience or clinical intuition.
What they do exceptionally well is recognize patterns, generate predictions, and process complexity at scale. That’s incredibly valuable, but it comes with important caveats.
AI models depend heavily on the quality and completeness of the data they’re trained on. And in biology, data is never clean or complete. It’s messy, variable, and deeply context-dependent.
There’s also the persistent challenge that correlation does not equal causation. Just because an AI system identifies a pattern doesn’t mean it has uncovered a true biological mechanism.
And perhaps most importantly, simulation is not reality. A model can approximate how a system behaves, but it cannot fully replicate the intricacies of a living organism.
So yes, AI can help us ask better questions and explore new possibilities. But it doesn’t remove uncertainty in our lives.
The Economics of Hope
There’s another dimension to this story that’s worth acknowledging, particularly in today’s interconnected world.
Scientific initiatives of this scale don’t exist in isolation. They operate within a broader ecosystem that includes media dynamics, institutional reputation, philanthropic influence, and technological competition.
In that ecosystem, hope becomes a kind of currency. The more ambitious the vision, the more attention it attracts. And attention, as we’ve learned in the digital age, is a powerful force. It drives engagement, shapes perception, and often determines which ideas gain traction.
This doesn’t mean the intentions behind these initiatives are flawed. But it does influence how the story is told and how it is received by the public.
More often than not, what reaches people isn’t the cautious, measured voice of the scientist. It’s the confident, forward-looking tone of the visionary.
A More Grounded Way to See It
So where does that leave us?
A more balanced interpretation of this initiative is not as a cure or a breakthrough, but as something quieter and, in many ways, more meaningful. It is an investment in the infrastructure of future discovery.
If it succeeds, it could improve how we model cellular systems, accelerate early-stage research, reduce the time and cost of testing new ideas, and support more personalized approaches to treatment.
Those are not small achievements. They may not make headlines in the same way, but they have the potential to save lives in very real and practical ways.
Not by eliminating disease altogether, but by helping us manage it with greater precision and insight.
The Scientist’s Perspective: Progress Is Incremental
One of the big challenges in communicating science is helping people appreciate just how incremental progress tends to be.
It’s not dramatic. It doesn’t unfold in neat, cinematic breakthroughs. Instead, it moves slowly, step by step, study by study, often with long periods where progress feels almost invisible.
When breakthroughs do occur, they are usually the result of decades of accumulated knowledge rather than a single moment of discovery.
We’ve seen this pattern with antibiotics, vaccines, imaging technologies, and countless other advances. There’s an initial wave of optimism, followed by periods of frustration and recalibration, and eventually a gradual integration into everyday practice.
AI in biology is likely to follow a similar path. It will evolve, improve, stumble, and refine itself over time.
Final Reflections: Between Cynicism and Blind Faith
It’s tempting to respond to announcements like this in extremes. Some dismiss them outright as hype. Others embrace them with uncritical enthusiasm.
Neither response does justice to the complexity of what’s actually unfolding. What we’re seeing is a convergence of powerful technologies, ambitious goals, and compelling storytelling. It’s neither a miracle nor a mirage. It’s something in between.
As thoughtful readers, the challenge is to hold two ideas at once: that this investment genuinely matters, and that it does not mean what the headlines might suggest.
That balance between curiosity and skepticism is where real understanding begins to take hold.
If artificial intelligence does transform medicine, and I suspect it will, in time. It won’t be because it suddenly “ended the disease.”
It will be because it helped us understand the human body, and perhaps even the human condition, a little more deeply.
And in the long arc of the science disciplines, that kind of understanding has always been the true breakthrough.
Here is a relevant story from the science world:
Déjà Vu of the Signals of the Storms in a Teacup: A Scholarly Conversation on Early Cancer…
When Even Fruits and Vegetables Look Dangerous: From AHA 2024 to AACR 2026: Are we witnessing a recurring pattern in…medium.com
By the way, I decided to start a series about scholarly sexual health stories on this platform and others. I introduced my goal and plan in a new story.
Why I’m Launching a Scholarly Sexual Health Series: A Public Health Perspective
Sexual health touches identity, relationships, wellbeing, and personal dignity, yet it remains one of the least openly…medium.com
You are welcome to contribute to this series on my publication, Health and Science, on Medium. I also plan to curate these stories on my Substack publication (Health & Science Research by Dr Michael Broadly) and guest blog on the Digitalmehmet community blogs. If my time allows, I might also compile a book with the content of my series to reach a broader audience.
You can find the submission guidelines for the ILLUMINATION Integrated Publications from the following links:
ILLUMINATION, Curated Newsletters, SYNERGY (Newsletter Booster), Technology Hits, Health and Science,ILLUMINATION Book Chapters, Readers Hope, ILLUMINATION Gaming,Videos/Podcasts, Magnetic Newsletter Pro, Substack Mastery Boost, ILLUMINATION Scholar (NEW), ILLUMINATION Local News and Documentaries (NEW), ILLUMINATION Retirement, Aging, and Legacy (NEW), ILLUMINATION Philosophy and Metaphysics (NEW)
Thank you for reading my stories and joining our publications.
About Me
I’m a retired healthcare scientist in my late-70s. I have several grandkids who keep me going and inspire me to write on this platform. I am also the chief editor of the Health and Science publication on Medium.com. As a giveback activity, I volunteered as an editor and content curator for Illumination publications, supporting many new writers. I will be happy to read, publish, and promote your stories. You may connect with me on LinkedIn, Twitter, and Facebook, where I share stories I read. You may subscribe to my account to get my stories in your inbox when I post. You can also find my distilled content on Substack: Health Science Research by Dr Mike Broadly.
Here is my latest curated collection: Mike’s Favorite Stories on ILLUMINATION Publications — #277
Leave a Reply